Related Experiment Video
Updated: May 16, 2026
08:48
In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
Device therapy in Chagas disease heart failure.
Reinaldo B Bestetti1, Augusto Cardinalli-Neto
1UNAERP Medical School, 14096-430 Ribeirão Preto, Brazil. rbestetti@netsite.com.br
Expert Review of Cardiovascular Therapy
|November 30, 2012
Summary
Chagas disease heart failure management lacks device therapy evidence. Cardiac resynchronization and implantable cardioverter-defibrillator therapies are used, but their efficacy in Chagas patients remains debated.
Area of Science:
- Cardiology
- Infectious Diseases
- Medical Devices
Background:
- Chagas disease is a leading cause of chronic heart failure in endemic regions.
- Current medical treatments for Chagas heart failure mirror those for non-Chagas patients.
- Evidence supporting device therapy for Chagas heart failure is limited.
Purpose of the Study:
- To review the current evidence and recommendations for device therapy in Chagas heart failure.
- To discuss the role of cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillators (ICDs) in managing Chagas cardiomyopathy.
Main Methods:
- Literature review of studies on device therapy in Chagas heart failure.
- Analysis of current clinical guidelines and expert opinions.
- Examination of electrophysiological testing and patient outcomes.
Main Results:
- Cardiac resynchronization therapy is recommended for Chagas heart failure with conduction disturbances (e.g., left bundle branch block) and advanced symptoms refractory to medical treatment, though controversial.
- Implantable cardioverter-defibrillator therapy is indicated for primary prevention of sudden cardiac death in patients with left ventricular ejection fraction <30%.
- ICD therapy is also recommended for secondary prevention and in patients with moderate left ventricular dysfunction and inducible arrhythmias.
Conclusions:
- Device therapy, including CRT and ICDs, plays a role in managing Chagas heart failure, particularly for conduction abnormalities and prevention of sudden cardiac death.
- Further evidence-based research is needed to solidify the role and optimize the use of device therapies in Chagas cardiomyopathy.
- Current recommendations suggest careful patient selection for device implantation in Chagas disease patients.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...